Navigation Links
Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Date:11/26/2007

ine. "We are pleased that this distinguished group from Johns Hopkins is supporting our efforts, and we look forward to working with all of our investigators in the coming year to generate clinical data enabling us to assess the potential of bavituximab as a possible new therapy for patients co-infected with HCV and HIV."

This open-label, dose escalation study is expected to enroll up to 24 patients chronically infected with HCV and HIV. Patient cohorts will receive ascending dose levels of bavituximab weekly for up to eight weeks. HCV and HIV viral titers and other biomarkers will be evaluated, although they are not formal study endpoints.

In the United States alone, an estimated 300,000 individuals are co-infected with HCV and HIV, representing up to 30% of all HIV-infected patients. Co-infected patients have been shown to have a lower response to current HCV treatment regimens, and the adverse effects of these regimens can be especially problematic for some HIV patients.

About Bavituximab

Bavituximab is a monoclonal antibody in a new class of anti-phosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses, including both HCV and HIV. Bavituximab helps stimulate the body's immune defenses to destroy both the virus particles and the infected cells. Since bavituximab's PS target comes from the host and not the virus, bavituximab may be less susceptible to the development of anti-viral resistance. Peregrine has completed two bavituximab Phase I monotherapy clinical trials in patients with chronic HCV infection. In these trials, the drug appeared safe and well tolerated with encouraging signs of anti-viral activity. Bavituximab is also in Phase II trials for the treatment of solid cancers.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015  Pomerantz ... Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com ... whether Vitae and certain of its officers and/or directors ... Exchange Act of 1934.  On February ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 8, 2010 Substandard and counterfeit versions of thirteen ... Ghana by the Medicines Quality Monitoring surveillance program. Set ... in collaboration with the U.S. Pharmacopeial Convention (USP) and ... samples antimalarials across the public and private sectors. It ...
... WEST PALM BEACH, Fla., Nov. 8, 2010 ... Use and Health, teens abuse prescription medications more ... teens are under the misconception that these highly ... drugs. (Logo: http://photos.prnewswire.com/prnh/20100901/FL58348LOGO) ...
Cached Medicine Technology:Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3Abuse Of Prescription Meds Among Teens Greater Than Most Illegal Drugs 2Abuse Of Prescription Meds Among Teens Greater Than Most Illegal Drugs 3
(Date:2/28/2015)... How would you describe your leadership ... all kinds of different leaders, each with their ... advantages and applications of different leadership styles, Ohio-based ... product this spring called The Leadership Report that ... personality type, leadership, and success. The Leadership Report ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... 28, 2015 Memphis, TN: MedixSafe has ... for a new security reader named Guardian 2. ... is a new biometric scanner that significantly increases ... features, the new biometric scanner provides fast and ... , MedixSafe narcotics lockers with Vanguard ...
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a common ... earlier than Whites/Caucasians or African Americans, according to a ... previous research indicated that Hispanics tend to have more ... published online in the journal Alcoholism: Clinical and Experimental ... pinpoint racial and ethnic disparities in the ages at ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2
... old-fashioned hard work, study says , , FRIDAY, Aug. ... exercise outcomes in people who have chronic obstructive ... , Creatine is a popular nutritional supplement used ... study included 100 COPD patients who received either ...
... of Diabetes and Digestive and Kidney Diseases (NIDDK) ... published several new resources to help people learn ... are among the most critical health problems in ... children and young adults. The publications address interstitial ...
... (Aug. 1, 2008) -- Quality of care varies greatly for ... of the country and category of health care facility, suggesting ... protocols, according to a new study that was published in ... Oncology (2008: Vol. 26, Issue 22). , The inconsistencies ...
... for completion of health risk assessment resulted in a 65% employee completion ... ... August 1, 2008 -- Employers are increasingly using incentives as the carrot ... issue brief from HealthFitness (OTC BB: HFIT) zeros in on the use ...
... consecutive year, Omega Institute will host an important conference at its ... disorders, to explore the latest research and development in treating and ... ... 1, 2008 -- For the second consecutive year, Omega Institute ...
... sleep apnea) is associated with an increased risk of ... Cohort, an 18-year observational study supported by the National ... Institutes of Health. Researchers found that adults (ages 30 ... the study were two to three times more likely ...
Cached Medicine News:Health News:Creatine Has Negligible Effect on COPD Exercise Rehab 2Health News:NIDDK publishes new resources about urologic and kidney disorders 2Health News:NIDDK publishes new resources about urologic and kidney disorders 3Health News:Disparities in prostate cancer treatment suggest ways to improve care 2Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 2Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 3Health News:Omega to Hold Conference: Autism Through the Life Span II 2Health News:Omega to Hold Conference: Autism Through the Life Span II 3Health News:Sleep apnea linked to increased risk of death 2
... is a unique microprocessor controlled shaking incubator ... either 96 or 384 well format. Speed, ... control panel and all are displayed on ... the clear protective cover. The Millennium 2000 ...
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... Ultracompact high end desktop multilaser flow ... any kind of cell analysis and absolute ... forward and two different side scatter signals ... channels. The new CyFlow ML instrument can ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: